3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Gynecologic
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm Metastasis
1
Breast Neoplasms
1
Interventions
Paclitaxel
83
Fulvestrant
65
Trastuzumab
62
Letrozole
61
pembrolizumab
53
Carboplatin
51
Cyclophosphamide
48
pertuzumab
46
palbociclib
44
Anastrozole
41
Capecitabine
33
Tamoxifen
30
Magnetic Resonance Spectroscopy
29
exemestane
28
Radiotherapy
28
Doxorubicin
28
ribociclib
26
olaparib
26
Docetaxel
26
Specimen Handling
25
abemaciclib
24
130-nm albumin-bound paclitaxel
20
trastuzumab deruxtecan
19
Taxes
19
Gemcitabine
19
durvalumab
18
Surveys and Questionnaires
18
Epirubicin
18
eribulin
17
Alpelisib
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Glucose
×
Breast
×
Clear all
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled